FORMULATION AND IN VITRO EVALUATION OF POLY-(D, L-LACTIDE-CO-GLYCOLIDE) (PLGA) NANOPARTICLES OF ELLAGIC ACID AND ITS EFFECT ON HUMAN BREAST CANCER, MCF-7 CELL LINE.
Keywords:Ellagic acid nanoparticles, TWEEN®20, Poly vinyl alcohol, MTT assay, Kinetic modelling
Objective: The aim of this experiment was to develop ellagic acid (EA) loaded poly (D,L-lactide-co-glycolide) (PLGA) nanoparticles for tumour-specific drug delivery. The phytochemical EA is a potential antioxidant, anticarcinogenic and antimutagenic. Due to its low solubility and permeability, it falls under class IV of the BCS classification.
Methods: PLGA nanoparticles were prepared by a method established on the concept of single emulsification–solvent evaporation by using TWEEN®20 as a cosolvent for solubilizing the drug. While developing this method, polyvinyl alcohol (PVA), was implemented.
Results: The stabilized formulation was with a particle size of 174.2 nm, which is ideal for tumour accumulation. The SEM images confirmed that the NPs have spherical shape. The resulting NPs were predominantly spherical and of uniform size and shape. Initial release of EA from nanoparticles in pH 7.4 phosphate buffer was quick, followed by a steady sustained release. The in vitro cytotoxicity study using MTT was also performed on the human breast cancer, MCF-7 cell line and EA-NPs were found to successively reduce the IC50 values which thereby revealed the pronounced cytotoxic effect of the formulation.
Conclusion: After performing this experiment, we can conclude that the polymeric nanoparticles are efficient and suitable form of drug delivery of ellagic acid exhibiting potential anti-tumour activity.
Garcia Diaz M, Foged C, Nielsen HM. Improved insulin loading in poly (lactic-co-glycolic) acid (PLGA) nanoparticles upon self-assembly with lipids. Int J Pharm 2015;482:84-91.
Das PJ, Paul P, Mukherjee B, Mazumder B, Mondal L. Pulmonary delivery of voriconazole loaded nanoparticles providing a prolonged drug level in lungs: a promise for treating fungal infection. Mol Pharm 2015;12:2651–64.
Bala I, Bhardwaj V, Hariharan S, Kharade SV, Roy N. Sustained release nanoparticulate formulation containing antioxidant-ellagic acid as potential prophylaxis system for oral administration. J Drug Target 2006;14:27–34.
Zhang T, Chen HS, Wang LF, Bai MH, Wang YC. Ellagic acid exerts anti-proliferation effects via modulation of Tgf-B/Smad3 signaling in MCF-7 breast cancer cells. Asian Pac J Cancer Prev 2014;15:273–6.
Baishya R, Nayak DK, Kumar D, Sinha S, Gupta A. Ursolic acid loaded PLGA nanoparticles: in vitro and in vivo evaluation to explore tumor targeting ability on B16F10 melanoma cell lines. Pharm Res 2016;33:2691–703.
Dang S, Sharma D, Philip G, Gabrani R, Ali J. Dual agents loaded polymeric nanoparticle: effect of process variables. Int J Pharm Investig 2015;5:155.
Babos G, Biro E, Meiczinger M, Feczko T. Dual drug delivery of sorafenib and doxorubicin from PLGA and PEG-PLGA polymeric nanoparticles. Polymers 2018;10:1–12.
Baishya H. Application of mathematical models in drug release kinetics of carbidopa and levodopa er tablets. J Dev Drugs 2017;6:1–8.
Kim HA, Lee RA, Moon BI, Choe KJ. Ellagic acid shows different anti-proliferative effects between the MDA-MB-231 and MCF-7 human breast cancer cell lines. J Breast Cancer 2009;12:85–91.
Kamaly N, Xiao Z, Valencia PM, Radovic Moreno AF, Farokhzad OC. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev 2012;41:2971–3010.
How to Cite
Copyright (c) 2021 JAYITA DAS, ANIMA DEBBARMA, H. LALHLENMAWIA
This work is licensed under a Creative Commons Attribution 4.0 International License.